Side-effect management of chimeric antigen receptor (CAR) T-cell therapy

Chimeric antigen receptor (CAR) T cells directed against the B-cell marker CD19 are currently changing the landscape for treatment of patients with refractory and/or relapsed B-cell malignancies. Due to the nature of CAR T cells as living drugs, they display a unique toxicity profile. As CAR T-cell therapy is extending towards other diseases and being more broadly employed in hematology and oncology, optimal management strategies of side-effects associated with CAR T-cell therapy are of high relevance. Cytokine release syndrome (CRS), immune effector cell-associated neurotoxicity syndrome (ICANS), and cytopenias constitute challenges in the treatment of patients with CAR T cells. This review summarizes the current understanding of CAR T-cell toxicity and its management.

Automated summary

CAR T-cell therapy targeting CD19-expressing B cells has shown promising results in treating refractory and/or relapsed B-cell malignancies, but also presents challenges such as cytokine release syndrome and neurotoxicity syndrome. Optimal management strategies for the side-effects associated with CAR T-cell therapy are crucial as it expands into other diseases in hematology and oncology.